



**NORDIC GROWTH  
SUMMIT**

Program Agenda  
10.26.2022



Presented By



**INNOVATION  
CENTRE  
DENMARK**  
DANISH IDEAS. GLOBAL SOLUTIONS.



W  
E  
L  
C  
O  
M  
E

## Welcome to our first annual Nordic Growth Summit.

We're so pleased to bring together our friends and colleagues for this special gathering.

When we were in the initial planning stages of imagining what the Nordic Growth Summit could be, we knew we wanted to create a gathering that was authentic and unique to the people with whom we work so closely in the United States and across Scandinavia and the European Union.

We wanted it to be an intimate gathering of friends who are deeply committed to Nordic-US collaboration. We wanted it to be a day of reflection, thought, challenge, and imagination, a day of exploring critical issues that all companies face, whether they be established or emerging. We hoped to come together and create business success predicated on our collective standards of effective and data-driven contributions to support international human health and ongoing partnership between the US and Scandinavia.

Back Bay Life Science Advisors conceived of a high-level and highly informative gathering in which to share the challenges and promises we face in our daily work. It is wonderful and only natural that Innovation Centre Denmark, Boston is our partner in this endeavor.

Back Bay Life Science Advisors, a longtime leader in forging US-Nordic life science strategy and transactional activities, and Innovation Centre Denmark, Boston, whose mission is to build bridges between Danish life science research institutions and organizations and the United States, have collaborated closely for many years. We have worked together throughout 2022 to create something a bit different and, we hope, memorable.

We're so pleased you've decided to join us for what we know will be an insightful day reflecting on our current business climate and what's needed to forge our path ahead to collectively lift the global life sciences sector.

We hope you take from this day information, newfound collegiality, reinforced friendships, data and thoughts conducive to your business expansion and your understanding of the challenges and opportunities abundant in the cross-border world.

Welcome to all our longstanding friends, our new friends and colleagues as well. We're so appreciative you've decided to join us this year for this inaugural event.

Here's to all of us being together again next year.





Sincerely,

JONATHAN P. GERTLER  
Chief Executive Officer,  
Back Bay Life Science Advisors

JOAN HENTZE  
Consul General &  
Chief Executive Officer,  
The Innovation Centre Denmark, Boston

# Schedule of Events

---

8:30-9:00 AM	<b>BREAKFAST AND REGISTRATION</b>
9:00-9:15 AM	<b>Welcome from Back Bay Life Science Advisors and Innovation Centre Denmark, Boston</b>
 9:15-10:00 AM	<b>Policy and Delivery Considerations Impacting C-Suite Decisions</b> John Osborn, Senior Advisor, Hogan Lovells <b>Alexander Natz</b> , Secretary General, The European Confederation of Pharmaceutical Entrepreneurs (EUCOPE) <b>Kelly Leggett</b> , Chief Clinical Transformation Officer, Cone Health <b>Moderated by Peter Bak</b> , Managing Director, Back Bay Life Science Advisors
 10:00-10:45 AM	<b>The CEO Journey Through Financing, Partnering and M&amp;A</b> Ian Nicholson, Trustee, LifeArc Donna J. Edmonds, CEO, BRAINBox Solutions <b>Moderated by Gregory Benning</b> , Managing Director, Head of Investment Banking, Back Bay Life Science Advisors
10:45-11:00 AM	<b>COFFEE AND CONVERSATION BREAK</b>
 11:00-11:45 AM	<b>Accelerating Public-Private Sector Opportunities to Further Enhance the Nordic Ecosystem</b> Kasim Kutay, Chief Executive Officer, Novo Holdings A/S Hanne Mette Dyrllie Kristensen, Chief Executive Officer, The Life Science Cluster Chris Coburn, Chief Innovation Officer, Mass General Brigham <b>Moderated by Jonathan Gertler</b> , Chief Executive Officer, Back Bay Life Science Advisors
11:45-12:45 PM	<b>LUNCH</b>
 12:45-1:30 PM	<b>The Next Big Thing in Medtech/Healthtech</b> Jens Nielsen, Chief Executive Officer, BioInnovation Institute Edward Kliphuis, Partner, Sofinnova Partners Kelly Leggett, Chief Clinical Transformation Officer, Cone Health <b>Marc Goldberg</b> , Co-founder and Managing Partner, BioVentures MedTech Funds Erik Wold, Investment Director, Investinor <b>Moderated by Jonathan Gertler</b> , Managing Partner, BioVentures MedTech Funds

---

 **1:30-2:15 PM The US and Nordic Public Markets: Strategies for a Successful Company**

**Kristopher Brown**, Partner, Life Sciences Group, Goodwin

**Seth T. Goldsamt**, Partner, McGuireWoods

**Per Langoe**, Chief Executive Officer, Palette Life Sciences

**James T. Cirezza**, Managing Director, DNB Markets

**Moderated by Gregory Benning**, Managing Director,  
Head of Investment Banking, Back Bay Life Science Advisors

---

**2:15-2:30 PM COFFEE AND CONVERSATION BREAK**

---

 **2:30-3:00 PM Beyond the Science: Macro-Economic Factors in Life Science Dealmaking**

**James T. Cirezza**, Managing Director, DNB Markets

---

 **3:00-3:45 PM Cross Border M&A, Licensing and Partnering & US Market Penetration**

**Camilla C. Collet**, Partner, Gorrissen Federspiel

**Kristopher Brown**, Partner, Life Sciences Group, Goodwin

**Per Langoe**, Chief Executive Officer, Palette Life Sciences

**Donna J. Edmonds**, CEO, BRAINBox Solutions

**Gregory Benning**, Head of Investment Banking, Back Bay Life Science Advisors

**Moderated by Stephan Gauldie**, Managing Director,  
Back Bay Life Science Advisors

---

**3:45-4:15 PM ROUNDTABLE DISCUSSIONS**

**I. Development and Commercialization Issues in Cell & Gene Therapy**

Led by Peter Bak

**II. Healthtech/Digital Health: Pathways to US Adoption**

Led by Jonathan Gertler

**III. Preparing for Your Cross-Border Transaction**

Led by Gregory Benning

**IV. Rare Disease and Oncology: Issues in Clinical Development**

Led by Stephan Gauldie

---

**4:15-4:30 PM CLOSING REMARKS**

---

**4:30-6:00 PM WINE RECEPTION AT EIGHTVEDS PAKHUS**

 Panel Discussion

 Fireside Chat

 Moderated Discussion

 Talk

Panels will be video recorded for educational purposes.  
Audience questions may be captured. If you prefer not to appear  
in these videos, please don't hesitate to let us know.

# About Our Guest Speakers



## PETER BAK

*Managing Director, Strategic Advisory, Back Bay Life Science Advisors*

Peter Bak, PhD is Managing Director at Back Bay Life Science Advisors. He has more than twelve years of experience with a broad range of research approaches and fields, from immunology and infection through oncology. Dr. Bak leads a diverse portfolio of projects with a focus on liquidity planning and positioning, strategic franchise building, M&A and licensing strategy, and buy-side diligence. He regularly works with companies of all scales, from startup to global life science brands.

Dr. Bak's research career in immuno-oncology began at Dartmouth Medical School (PhD, Microbiology and Immunology), where his research uncovered novel pathways of immunosuppression in ovarian cancer. His research continued at MIT, as an American Cancer Society Postdoctoral Fellow at the Koch Institute of Integrative Cancer Research.

More: [www.bblsa.com](http://www.bblsa.com)



## CAMILLA C. COLLET

*Partner, Gorrissen Federspiel*

Camilla C. Collet assists Danish and international companies with M&A transactions, commercial contracts, reorganizations and other transactions, often of an international nature and where the understanding of commercial principles is paramount. Camilla has particular expertise in the life sciences segment where she has assisted with numerous acquisitions, sales and investments in life sciences companies.

She advises pharmaceutical companies, biotech companies and manufacturers of medical devices on a current basis. Camilla also has experience with transactions within, among other things, industry, real property, insurance and the entertainment industry. As head of our Compliance & CSR cross-practice group, Camilla advises on anti-corruption, export control, sanctions and business ethics, among other things. Finally, Camilla has experience with board duties and regularly lectures on M&A, Contracts and Compliance.

More: [www.gorrissenfederspiel.com](http://www.gorrissenfederspiel.com)



## KRISTOPHER BROWN

*Partner, Goodwin Procter*

Kristopher Brown is a law partner in the Life Sciences group at the global law firm Goodwin Procter LLP. Mr. Brown, who is based in the firm's New York City office, advises on corporate and transactional matters for numerous financial and corporate strategic investors as well as emerging growth companies principally in the life sciences and healthcare sectors.

Mr. Brown has experience in the full range of complex commercial transactions, including public offerings, licensing transactions, mergers and acquisitions, divestitures, royalty monetizations, the formation of investment partnerships, and the creation of strategic and collaborative alliances and joint ventures. Practicing for 30 years, Mr. Brown has advised on more than 250 transactions in the life sciences sector alone. In addition, he counsels investors, management executives, and boards of directors on governance and regulation issues and securities law matters.

More: [www.goodwinlaw.com](http://www.goodwinlaw.com)



## JAMES T. CIRENZA

*Managing Director, DNB Markets*

Jim Cirenza is Managing Director & Head of Institutional Sales and Trading, DNB Markets.

He has more than 40 years of experience in the securities sales and trading business with such firms as Goldman Sachs (12 years) and JP Morgan (3 years). From 2001 to 2006, he was the President of Carnegie's U.S. activities and subsequently from 2006 to 2009 he was the Global Head of Carnegie's securities business.

More: <https://www.linkedin.com/in/james-t-cirenza-1a90411/>

# About Our Guest Speakers



## CHRIS COBURN

*Chief Innovation Officer, Mass General Brigham*

Chris Coburn is Chief Innovation Officer, Mass General Brigham, an integrated health care system that consists of Harvard University affiliates Brigham and Women's Hospital, Massachusetts General Hospital, Massachusetts Eye and Ear, and McLean Hospital. Mass General Brigham is the nation's largest academic research enterprise with over \$13 billion in annual revenue, 1.5 million patient visits and \$2 billion in research expenditures. It also has a managed care organization, out-patient facilities and community hospitals. Its 4,200 faculty are appointed at Harvard Medical School.

Mr. Coburn leads a team of more than 140 tasked with the worldwide commercial application of the unique capabilities and discoveries of Mass General Brigham's 82,000 employees. His unit's business development responsibilities include investing, company creation, innovation management, industry collaborations, and licensing. Commercialization revenue exceeds \$200 million annually and more than 300 companies have been spun-off from Mass General Brigham in the last decade. Large-scale industry collaborations have been established in areas such as AI and drug development. His group also manages a nearly \$500 million venture fund.

More: [www.massgeneralbrigham.org](http://www.massgeneralbrigham.org)



## DONNA J. EDMONDS

*Chief Executive Officer, BRAINBox Solutions*

Donna has 30+ years of healthcare experience, beginning as a critical care nurse, and migrating to operating and senior management in hospital, physician group practices, and then diagnostic industry positions.

She spent 8+ years with Baxter in senior (group) executive positions in business development, sales and marketing of clinical products aimed at improving care and reducing health care costs. She served in senior management roles for 10 diagnostic companies providing key leadership in two company exits and is a recognized leader in Cardiovascular Diagnostics, changing clinical practice in this space

She formed Virginia Life Sciences Investments, Inc. and led Series A investment in ImmunArray, the original home of a broad portfolio of biomarkers for Neurological Disease Diagnosis and Monitoring.

More: <https://brainboxinc.com/our-team/>





## STEPHAN GAULDIE

*Managing Director, Strategic Advisory, Back Bay Life Science Advisors*

Stephan Gauldie, PhD is a Founding Member of Back Bay Life Science Advisors and Head of Back Bay's Canadian Operations. Dr. Gauldie helped build Back Bay's integrated strategic advisory and investment banking offering for life science companies at every stage. Dr. Gauldie's role emphasizes commercial assessment and forecasting, strategic franchise-building, M&A and licensing strategy, buy-side diligence, and exit planning with defensible, analysis-driven positioning for venture-backed companies.

Dr. Gauldie is also a member of Back Bay's investment banking team, providing forecasting, valuation, market, and scientific analytics in sell-side transactions, buy-side engagements, and financing support. He has more than 20 years of experience across drug development research, market analysis, and strategy consulting.

More: [www.bbbsa.com](http://www.bbbsa.com)



## EDWARD KLIPHUIS

*Partner, Sofinnova Partners*

Edward Kliphuis is a partner at Sofinnova Partners focused on Digital Medicine investments. Previously, Edward was at M Ventures, the €1bn AUM corporate VC-arm of Merck KGaA, where he was responsible for health-tech investments. Edward led, among others, investments in Akili Interactive Labs (the first-ever FDA-approved prescription video game); Wiliot (battery-free Bluetooth tags with infinite lifetime, enabling a true connected-everything), and Biolinq (wearable continuous biosensing platform). Before M Ventures, Edward was in the Life Sciences securities team at Kempen & Co, a pan-European merchant bank, covering listed small- and mid-cap Life Sciences equities.

More: [www.sofinnovapartners.com](http://www.sofinnovapartners.com)

# About Our Guest Speakers



## **JONATHAN P. GERTLER**

*Chief Executive Officer, Back Bay Life Science Advisors  
Managing Partner, BioVentures MedTech Funds*

Jonathan P. Gertler, MD is Chief Executive Officer of Back Bay Life Science Advisors. He has over 35 years of clinical and scientific experience, and extensive advisory work with biotechnology, medical device, diagnostic, and health care IT companies in both the private and public sectors. A former vascular surgeon, Dr. Gertler is a frequent speaker and writer on strategic issues facing life science companies at all stages.

He has founded several life sciences companies, including Antyllus Therapeutics; a development-stage biotechnology company focused on aortic diseases, and Optivio, a commercial-stage enterprise software platform for stress management and performance optimization. Dr. Gertler also founded Cardiovascular Technologies, an endovascular company that successfully exited in 2001.

More: [www.bblsa.com](http://www.bblsa.com)



## **SETH T. GOLDSAMT**

*Partner, McGuireWoods*

Seth Goldsamt advises his US and international clients (including investment funds) on a broad range of mergers and acquisitions, private equity transactions, public and private securities offerings (including PIPE transactions), equity co-investments, joint ventures, mezzanine financings, venture capital, and restructuring transactions.

Particularly experienced in representing clients in the technology, media and telecommunications (TMT) and technology/biotechnology industries and in advising on international/cross-border transactions, Seth also advises clients on general corporate matters, various aspects of corporate governance and compliance with federal securities laws.

Seth is an active member of The Danish-American Chamber of Commerce, New York, and has served on its board of directors for several years and, since 2021, has served as its chairman.

More: [www.mcguirewoods.com](http://www.mcguirewoods.com)



## JOAN HENTZE

*Consul General & Chief Executive Officer, The Innovation Centre Denmark, Boston*

Joan Hentze is Consul of Denmark in Boston, and Head of Life Science & Health Innovation in North America. Joan has been the Executive Director of Innovation Centre Denmark Boston since 2019. Before her current role, Joan was the Deputy Consul General at the Danish Consulate in New York. She is expatriated from the Ministry of Foreign Affairs of Denmark, where she was the Global Industry Team Leader for the healthcare industry. In this position, she was leading an international team of 25 highly specialized healthcare experts specializing the developing and implementing of a growth plan for the Danish healthcare sector.

Prior to this role, Joan was a Health Counselor in the Royal Danish Embassy in Paris.

More: <https://thetradecouncil.dk/en/services/innovation/advisory/market-introduction>



## MARC GOLDBERG

*Co-Founder and Managing Partner, BioVentures MedTech Funds*

Marc Goldberg, JD, MBA, is Co-Founder and Managing Partner of BioVentures Investors. He brings well over 35 years of managerial and investment experience in the healthcare sector.

Prior to joining BioVentures Investors, Marc served as President and CEO of the Massachusetts Biotechnology Research Institute. Marc was Vice President, Finance and Corporate Development, CFO, and Treasurer at Safer, Inc., a developer and manufacturer of novel biopesticides and related products, and started his career at Genetics Institute, one of the earliest biotechnology research and development companies.

More: [www.bioventuresinvestors.com](http://www.bioventuresinvestors.com)

# About Our Guest Speakers



## HANNE METTE DYRLIE KRISTENSEN

*Chief Executive Officer, The Life Science Cluster*

Hanne Mette D. Kristensen has a solid background both as an entrepreneur and biotech CEO; she also has broad experience from clusters, both as an active member, and as a member of the Board of Directors of Oslo Cancer Cluster and Norway Health Tech. She has also worked on the incubator / investor side of the industry and has a broad international network.

Hanne Mette came to The Life Science Cluster from Innovation Norway where she was special advisor for life science / health in the greater Oslo region and Invest in Norway. Through the years in Innovation Norway she has worked with financing, companies and clusters, in addition to national and international branding of the industry for collaboration partners and investors. She has been responsible for a joint Nordic pavilion and collaboration at the BIO International Convention, international Global Growth and business networks within health, and for the coordination of strategic positioning of Norwegian health industry that was launched in 2019.

More: [www.thelifesciencecluster.no](http://www.thelifesciencecluster.no)



## ERIK WOLD

*Investment Director, Investinor*

Erik Wold holds a Master of Business and Economics from HHN. He has previously worked in Deloitte. Before joining Investinor he was Head of Venture at NTNU Technology Transfer AS (NTNU TTO), a company he co-founded back in 2003. After many years at Gløshaugen he joined the Investinor team in 2019 where he focuses primarily on software and health companies.

More at: <https://investinor.no/en/team/>



## GREGORY BENNING

*Managing Director, Head Investment Banking, Back Bay Life Science Advisors*

Gregory Benning is Managing Director and Head of Investment Banking at Back Bay Life Science Advisors. He is a highly experienced M&A specialist, with over 25 years of client advisory and transactional experience. He has managed and executed more than 300 M&A, divestiture and financing transactions, with proceeds totaling over \$15B.

Before joining Back Bay in 2013, Mr. Benning was Head of M&A for the emerging growth investment bank, Adams Harkness, and a partner-level banker at the Boston-based investment bank, Tucker Anthony. He launched middle-market M&A practices for A.G. Edwards & Sons and Barrington Associates, both now part of Wells Fargo.

More: [www.bbbsa.com](http://www.bbbsa.com)



## JOHN E. OSBORN

*Senior Advisor, Hogan Lovells*

John E. Osborn has been a life sciences industry executive, board member, lawyer, lecturer, writer and diplomat. He currently works as a senior advisor with the international law firm Hogan Lovells and a venture partner with BioVentures MedTech Funds. He also has been a healthcare industry advisor with the private equity firm Warburg Pincus, and a board member of publicly traded and privately held companies in the specialty pharmaceutical, healthcare IT and biomedical device sectors. For more than twenty years, John was a senior executive and general counsel with notable life sciences and healthcare companies, including Cephalon, US Oncology, Onyx Pharmaceuticals and Dendreon.

More: [www.bioventuresinvestors.com](http://www.bioventuresinvestors.com)

# About Our Guest Speakers



## KASIM KUTAY

*Chief Executive Officer, Novo Holdings A/S*

Kasim Kutay is Chief Executive Officer of Novo Holdings A/S, Denmark, a position he has held since September 1, 2016. He is a member of the board of Novo Nordisk A/S, Denmark, of Novozymes A/S, Denmark, of Evotec SE, Germany and of the Life Sciences Advisory Board of Gimv NV, Belgium.

From 2009 to 2016 Kasim Kutay was managing director, co-head of Europe and member of the Global Management Committee of Moelis & Co., UK. From 1989 to 2007 Mr Kutay held a number of positions at Morgan Stanley, UK, including chair of the European Healthcare Group.

More: [www.novoholdings.dk](http://www.novoholdings.dk)



## PER LANGOE

*Chief Executive Officer, Palette Life Sciences*

After spending time at Pharmacia Corporation, Q-Med, Galderma and Nestlé Skin Health, Per Langoe founded Palette Life Sciences with Travis Gay and Ole Mikkelsen with a vision to develop products that provide better quality of life to people around the globe. Per brings a unique combination of vast international experience and solid commercial tenure along with what he calls “enough background in development and manufacturing to be dangerous.” He oversees the overall operations and resources at Palette and acts as the main point of communication between the board of directors and the management team.

While other Life Science companies tend to have a more “paint by numbers” approach to product innovation, Per has a different view. “Product technology is critical but our culture, people and processes are equally vital. We focus on how to cultivate and drive innovation and use that innovation and passion to elevate patient care.”

More: [www.palettelifesciences.com](http://www.palettelifesciences.com)



## KELLY LEGGETT

*Chief Clinical Transformation Officer, Cone Health*

Kelly Leggett, MD has served as the Chief Clinical Transformation Officer for Cone Health since October 2018. In this role, she looks at standardizing care in ways that improve the quality and lower the costs for patients across Cone Health.

Leggett is a practicing obstetrician and gynecologist with the Center for Women's Health Care (i.e. faculty practice) at Cone Health. She previously led the faculty for a decade as the medical director.

Leggett is a graduate of the University of North Carolina at Chapel Hill and the Wake Forest University School of Medicine. She later served as chief resident of the obstetrics and gynecology residency program at Long Island Jewish Medical Center in New Hyde Park, New York.

More: [www.conehealth.com](http://www.conehealth.com)



## ALEXANDER NATZ

*Secretary General, The European Confederation of Pharmaceutical Entrepreneurs*

Alexander Natz is Secretary General of the European Confederation of Pharmaceutical Entrepreneurs (EUCOPE) in Brussels and advises innovative pharmaceutical and biotech companies, including start-ups, in regulatory and pricing & reimbursement matters from the EU law and German law perspective.

From 2008 to 2013, he was Head of the Brussels Office of Bundesverband der Pharmazeutischen Industrie e.V. (BPI). Before, he worked as a lawyer at Sträter Law Firm in Germany with a special focus on managed entry agreements and licensing of pharmaceuticals. Dr. Natz has also worked in the field of competition law with the European Commission and in the pharmaceutical industry. As a research assistant at Duke University (USA) he has dealt with international pharmaceutical law. His doctorate was supervised by the former judge at the European Court of Justice, Prof. Dr. Ulrich Everling.

More: [www.eucope.org](http://www.eucope.org)

# About Our Guest Speakers



## IAN NICHOLSON

*Trustee, LifeArc*

Ian Nicholson has over 35 years of international experience in management and transactions within the life sciences sector. He is chairman of Bioventix plc and a non-executive director at Clinigen Group plc. Currently he is also an operating partner at London-based Advent Life Sciences LLP, a leading life science venture investor.

Ian previously spent eight years as CEO of the privately held anti-fungal drug development company F2G Limited and before that was CEO of the oncology R&D company, Chroma Therapeutics Limited. Prior to that he was senior vice president, business development at UK biotechnology company Celltech Group plc.

Ian has worked extensively in licensing, mergers and acquisitions and market development in the UK, Europe and the US and holds a BSc (Hons) from University College London and an MBA from Boston University.

More: [www.lifearc.org/](http://www.lifearc.org/)



## JENS NIELSEN

*Chief Executive Officer, BioInnovation Institute*


Jens Nielsen is the CEO of BioInnovation Institute and a professor at Chalmers University of Technology and adjunct professor at DTU with a vast amount of life-science research experience.

He is an internationally respected scientist who has published more than 800 scientific articles that have been cited more than 87,000 times and with a current H-index of 133. He has received numerous awards, including the Novozymes Prize, the ENI Prize, the Eric and Sheila Samson Prime Ministers Prize for Innovation in Alternative Fuels for Transportation, Nature Award for Mentoring, the Emil Chr. Hansen Gold Medal, and the Gold Medal from the Royal Swedish Academy of Engineering Sciences. In 2019 he was honored as Knight, Ridder af Dannebrog, from Her Majesty The Queen of Denmark, for his meritorious service and contribution to science.

More: [www.bii.dk](http://www.bii.dk)



# Notes and Connections





## ABOUT Back Bay Life Science Advisors

*Strategic Guidance and Investment Banking for Global Biopharma, Medtech and Healthtech Supporting US-Nordic Collaboration and Growth*

Back Bay Life Science Advisors is a globally respected boutique consultancy known for pairing expert strategy with investment banking guidance and execution with a special emphasis on US-EU life science partnerships. They have been particularly dedicated to the Nordic region and are strong advocates for Nordic life science companies, both large and small.

Back Bay has built a strong track record and high-profile presence in Europe with project execution experience and contacts across Scandinavia, the UK, France, Belgium, the Netherlands, Germany, Switzerland and Italy. Globally, their advisors have nurtured relationships with all major biopharma, medtech companies and venture capital groups. Strategy clients include a broad spectrum of dominant Nordic biotech, pharmaceutical and MedTech companies.

Our Nordic transactions include Action Pharma, EpiTherapeutics, TopoTarget, Zymenex, Palette Life Sciences, and many others.

Back Bay provides supportive work for Nordic events, such as the Nordic American Life Science Conference, the DKBio Nordic Mentor Network for Entrepreneurship (NOME), Nordic Life Science Days, Nordic AMPLify and others. Back Bay serves as partners to leading Nordic organizations including The Life Science Cluster (Norway) and The BioInnovation Institute Foundation (BII), an international non-profit supported by the Novo Nordisk Foundation (Denmark).

Back Bay understands that the Nordic life science ecosystem represents best-in-class life science management, technology and financial expertise and excellence.

Back Bay Life Science Advisors  
545 Boylston Street  
Boston, MA 02116

+1 617.236.0954  
[www.bbbsa.com](http://www.bbbsa.com)

Please subscribe for Back Bay's life science industry updates and listen to our podcast at [www.bbbsa.com](http://www.bbbsa.com).

# Nordic Growth Summit Partners



## ABOUT Innovation Centre Denmark, Boston

The Innovation Centres are established in a cooperation between the Ministry of Higher Education and Science, and the Ministry of Foreign Affairs of Denmark.

The Innovation Centre Denmark Boston (ICDK Boston) supports Danish science and innovation through our extensive knowledge of the Boston innovation ecosystem. They facilitate collaboration between research institutions, start-ups, SMEs, and large corporations from Denmark and Boston. We have a specific focus on accelerating the entry of Danish Life Science and Green Tech companies into the US by identifying relevant collaborators, professional and academic networks, and investors.

ICDK Boston has the expertise to provide Danish companies with short- and long-term counsel on the most effective strategies to facilitate innovation and thereby internationalization. As part of the Danish government, they help businesses in strengthening their relationships with innovation stakeholders and their overall presence in the US, providing valuable opportunities for companies to expand within the fields of life sciences, hospitals and green transition. They also identify the latest trends in green transition, biotech, bioconvergence, and bio-solutions, and frequently share their insights through their media platforms, thematic reports, research webinars, and consultations with companies and universities.

Boston is the latest addition to the group of seven Innovation Centres globally.

The Innovation Centre Denmark, Boston  
50 Milk St 17th Floor Fornax, A Suite  
Boston, MA 02109

+1 857.770.0838

<https://icdk.dk/our-locations/boston>



## **NORDIC GROWTH SUMMIT**

**October 26, 2022**

**Eigtveds Pakhus  
Strandgade 25D  
1401 København, Denmark**

**Presented by:**

**Back Bay Life Science Advisors  
[bblsa.com](http://bblsa.com)**

**Together with:**

**Innovation Centre Denmark, Boston  
[usa.um.dk/en](http://usa.um.dk/en)**